CorVista Health
CorVista Health is a Bethesda-based private medical device company that markets the FDA-cleared CorVista System, a non-invasive, point-of-care cardiac diagnostic platform that applies machine-learned algorithms to identify pulmonary hypertension and coronary artery disease (including INOCA) from a 3.5-minute test, serving cardiologists, primary care physicians, and hospital outpatient settings.
- Company typePrivate
- Founded2012
- HeadquartersBethesda, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What CorVista Health does
CorVista Health, Inc. is a privately held medical device company (Delaware corporation, headquartered in Bethesda, MD) that markets the FDA-cleared CorVista System, a non-invasive, point-of-care cardiovascular diagnostic platform. The System synchronously collects cardiac and hemodynamic signals during a 3.5-minute test and transmits them to cloud-based processing, where proprietary machine-learned algorithms identify patterns associated with pulmonary hypertension and coronary artery disease — including ischemia with non-obstructive coronary arteries (INOCA) — and return results to a physician web portal in under 30 minutes, without radiation, contrast agents, injections, fasting, or exercise. The product is positioned as the world's first digital health solution cleared to aid diagnosis of both PH and CAD in a single test, with the PH Add-on additionally holding FDA Breakthrough Designation and validation in clinical trials of more than 11,000 patients.
The company is a subsidiary of Analytics For Life, Inc., which develops and manufactures the CorVista System and licenses it exclusively to CorVista Health. Revenue is generated through a combination of FDA-cleared device placement, per-test cloud processing, and the underlying licensing relationship with the parent. The go-to-market is built around a direct enterprise sales motion targeting cardiology specialty practices, primary care offices, and hospital outpatient settings — supported by a dedicated inbound demo process, a physician web portal that scales via internet connectivity, and a distribution pathway into cardiology group practices through Cardiovascular Associates of America (CVAUSA), the largest PE-sponsored CV platform in the US, whose CEO Tim Attebery chairs CorVista's board. The 11-50 person team is led by President & CEO Adrian Lam (ex-Stryker, ex-Genesis Medtech) with a leadership bench drawn from Janssen, Medtronic/Covidien, and Siemens/GE Healthcare.
Cumulatively, CorVista has raised approximately $93.9 million across disclosed funding rounds from 2015 to 2021, with a $65M Series 3 round in March 2021 led by Ambix Life Science Fund and MedVenture Partners. The most recent 12 months have been characterized by an inflection from regulatory and clinical validation to commercial scale: FDA 510(k) clearance of the CorVista System with CAD and PH Add-ons, FDA Breakthrough Designation for CorVista-PH, ACC.26 data presentation in March 2026, a Mayo Clinic research collaboration in April 2026, and the appointment of a new Chief Customer Officer and Chief Strategy Officer in May 2026.
CorVista Health firmographics
Firmographics- Name
- CorVista Health
- Legal name
- CorVista Health, Inc.
- Website
- https://corvista.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CorVista Health is a Bethesda-based private medical device company that markets the FDA-cleared CorVista System, a non-invasive, point-of-care cardiac diagnostic platform that applies machine-learned algorithms to identify pulmonary hypertension and coronary artery disease (including INOCA) from a 3.5-minute test, serving cardiologists, primary care physicians, and hospital outpatient settings.
- Ownership category
- akta.pro rank
CorVista Health industry classification
Industry- Product category
- Cardiac Diagnostic Devices
- NAICS
- Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215), Computer Systems Design and Related Services (54151)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer) (HLAHAOAC)
- akta.pro secondary industries
- Diagnostic & Triage Decision Support (HLACAGAA), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)
Keywords
Where CorVista Health is headquartered
LocationHeadquarters
- HQ city
- Bethesda
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CorVista Health business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- CorVista System Hardware & FDA-Cleared Device Sales: Revenue from sales/placement of the FDA-cleared CorVista System (510(k) device with CAD Add-on and PH Add-on) to clinical practices. The CorVista System is developed and manufactured by Analytics For Life, Inc., and licensed exclusively to CorVista Health, indicating a hardware/device-led revenue stream with underlying licensing economics from the parent.
- Licensing from Analytics For Life, Inc. The CorVista System is licensed exclusively to CorVista Health by its parent company, Analytics For Life, Inc., which develops and manufactures the platform. This implies a licensing/royalty relationship between the entities.
- Cloud-Based Diagnostic Service (Per-Test): Each test is captured via a 3.5-minute non-invasive procedure and processed in the cloud with results returned in under 30 minutes — typical of a per-test or managed service consumption model bundled with the device.
Go-to-market motion4 records
Distribution channels4 records
Marketing channels6 records
CorVista Health product offering
Product offeringCore offering
CorVista Health develops and commercializes the CorVista System, an FDA-cleared, non-invasive point-of-care diagnostic platform that uses proprietary machine-learning algorithms applied to simultaneously acquired cardiac and vascular signals to detect coronary artery disease (CAD) and pulmonary hypertension (PH) in symptomatic patients, delivering results in under 30 minutes without radiation, contrast, or exercise stress. The system is sold to cardiology practices, primary-care offices, and hospitals via a hardware sensor kit and a cloud-hosted physician portal, with add-on modules (CAD Add-on, PH Add-on) available for specific indications.
Product overview
CorVista Health offers a single integrated diagnostic platform — the CorVista System — with two cleared add-on modules (the CAD Add-on and the PH Add-on / CorVista-PH test). Together these form the world's first FDA-cleared digital health solution approved to aid diagnosis of both pulmonary hypertension and coronary artery disease in a single non-invasive, point-of-care test. The platform combines a 3.5-minute physiologic signal capture device with cloud-based machine-learned analytics and a physician web portal that returns same-day results. CorVista-PH additionally carries FDA Breakthrough Designation. The System is developed and manufactured by Analytics For Life, Inc. and licensed exclusively to CorVista Health, Inc.
Differentiator
Problem solved
Functional benefit
Brands
- CorVista System: FDA-cleared, non-invasive cardiovascular diagnostics platform that analyzes cardiac and hemodynamic signals using machine-learned algorithms; includes CAD Add-on and PH Add-on, each cleared as 510(k) devices.
Products and services
- CorVista System
Quantifiable outcome
- Machine-learned ischemia model achieved 90% sensitivity, 99% negative predictive value, AUC 0.86 (with 91% sensitivity in epicardial CAD and 86% in INOCA)
- +3 more outcomes
Companies that use CorVista Health
Customer profileSegments5 records
Ideal customer profiles2 records
CorVista Health technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature5 records
CorVista Health partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and minor.
- Mayo ClinicflagshipResearch collaboration announced April 28, 2026 to evaluate how the FDA-cleared CorVista-PH test may improve detection, risk stratification, and referral accuracy for patients with suspected pulmonary hypertension. The prospective observational study combines Mayo Clinic's cardiovascular research and pulmonary vascular disease expertise with CorVista's machine-learned diagnostic technology. Mayo Clinic has a financial interest in the referenced technology and will use any revenue to support its not-for-profit mission.
- Analytics For Life, Inc.coreAnalytics For Life, Inc. is CorVista Health's parent company. It develops and manufactures the CorVista System and licenses the technology exclusively to CorVista Health, Inc., which markets, sells, and supports it. Ian Shadforth originally joined Analytics for Life in 2015 and served as VP/GM of CorVista Health before becoming Chief Strategy Officer.
- MD+DI Online (mddionline)minorMD+DI Online featured CorVista as one of five medtech case studies (alongside Materna Medical, Profound Medical, Voyager Biomedical, and Efemoral Medical) examining how medtech companies can transform clinical trials from regulatory obligations into strategic competitive advantages.
- American College of Cardiology (ACC.26 Annual Scientific Session)coreCorVista presented new data on its non-invasive point-of-care test for ischemia (including INOCA) at ACC.26 in New Orleans, March 28-30, 2026, and exhibited its FDA-cleared CorVista System. Data showed 90% sensitivity and 99% negative predictive value for ischemia detection.
Scale indicators8 records
Recent moves6 records
Expansion highlights6 records
CorVista Health competitors and assessment
Company assessmentDirect peers
- HeartFlow: HeartFlow provides AI-driven, non-invasive coronary CT-derived FFR analysis for CAD diagnosis — directly competing with CorVista's CAD Add-on in non-invasive AI-enabled coronary artery disease detection at the point of care.
- Cleerly: Cleerly applies machine learning to coronary CTA to characterize plaque and diagnose CAD non-invasively — a direct competitor in AI-enabled cardiovascular diagnostics with similar physician-portal workflows.
- CathWorks: CathWorks offers the FFRangio system for non-invasive, AI-based coronary physiology assessment in the cath lab — competing with CorVista's CAD workflow targeting interventional cardiologists and catheterization labs.
Emerging players
- Cardio Diagnostics Holdings: Cardio Diagnostics uses AI-driven epigenetics and blood-based biomarkers for cardiovascular disease risk assessment — an emerging AI-native cardiovascular diagnostics competitor with overlapping physician-office workflow.
- Elucid Bioimaging: Elucid develops AI-based analysis of cardiovascular imaging for plaque characterization and risk — overlapping with CorVista's mission of non-invasive, AI-enabled cardiovascular risk detection.
- Eko Health: Eko Health combines AI-enabled digital stethoscopes and cardiac monitoring with FDA-cleared algorithms — competing at the point-of-care cardiovascular screening layer where CorVista also operates in primary care offices.
Broad incumbents
- GE HealthCare: GE HealthCare is a broad incumbent in cardiac imaging (CT, MR, ultrasound) and ECG, with deep hospital relationships and the ability to bundle AI diagnostics into cardiology platforms — a primary competitive incumbent for CorVista in the hospital segment.
- Philips: Philips is a broad incumbent in cardiovascular imaging (iCT, intravascular imaging, ECG) and has invested in AI-driven cardiology analytics — overlapping with CorVista across the cardiology diagnostic workflow.
- Siemens Healthineers: Siemens Healthineers is a global incumbent in cardiac imaging (CT, MR, ultrasound) and AI-augmented diagnostics — overlapping with CorVista in cardiovascular imaging and physician decision-support workflows.
Others
- Tempus AI: Tempus applies AI across precision medicine and has expanded into cardiology including pulmonary hypertension — a thematic adjacent AI-diagnostics platform rather than a direct point-of-care device competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
CorVista Health social profiles
Digital presenceCorVista Health financial estimates
Financial estimateRevenue estimate
Valuation estimate
CorVista Health leadership team
Management profileNumber of profiles
Profiles16 records
CorVista Health funding detail
Funding detailFunding overview
Funding rounds4 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CorVista Health M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CorVista Health
What does CorVista Health do?
CorVista Health develops and commercializes the CorVista System, an FDA-cleared, non-invasive point-of-care diagnostic platform that uses proprietary machine-learning algorithms applied to simultaneously acquired cardiac and vascular signals to detect coronary artery disease (CAD) and pulmonary hypertension (PH) in symptomatic patients, delivering results in under 30 minutes without radiation, contrast, or exercise stress. The system is sold to cardiology practices, primary-care offices, and hospitals via a hardware sensor kit and a cloud-hosted physician portal, with add-on modules (CAD Add-on, PH Add-on) available for specific indications.
Is CorVista Health a public or private company?
CorVista Health is a private company. It is classified as corporate owned and is currently operating.
When was CorVista Health founded?
CorVista Health was founded in 2012. It employs 11 to 50 people.
Where is CorVista Health based?
CorVista Health is headquartered in Bethesda, United States, in the North America region.
How does CorVista Health make money?
Three revenue lines are on record. CorVista System Hardware & FDA-Cleared Device Sales are the primary driver. The others are licensing from Analytics For Life, Inc and cloud-Based Diagnostic Service (Per-Test).
Who are CorVista Health's main competitors?
Direct peers on record are HeartFlow, Cleerly and CathWorks. Emerging players are Cardio Diagnostics Holdings, Elucid Bioimaging and Eko Health. Broad incumbents are GE HealthCare, Philips and Siemens Healthineers. Tempus AI is listed as an others.
Does CorVista Health have an API?
No public API is recorded for CorVista Health.
What industry is CorVista Health in?
CorVista Health's product category is Cardiac Diagnostic Devices. Its primary akta.pro industry code is HLAHAOAC, Cardiac & Coagulation POCT (Troponin, BNP, INR/aPTT, D-dimer), with a secondary code of HLACAGAA, Diagnostic & Triage Decision Support. Its NAICS code is 62151 and its SIC code is 3841.